| Code | CSB-RA023984MB15HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Urelumab, targeting TNFRSF9 (tumor necrosis factor receptor superfamily member 9), also known as CD137 or 4-1BB. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a crucial role in enhancing immune cell activation, proliferation, and survival. Upon binding with its ligand 4-1BBL, TNFRSF9 delivers potent secondary signals that amplify T cell responses and promote cytotoxic activity. This pathway is particularly relevant in cancer immunology, as TNFRSF9 activation can enhance anti-tumor immunity and overcome immune suppression within the tumor microenvironment.
Urelumab is an investigational agonistic antibody designed to stimulate TNFRSF9 signaling and boost immune responses against cancer cells. This biosimilar antibody serves as a valuable research tool for investigating CD137-mediated immune activation mechanisms, evaluating combination immunotherapy strategies, and studying T cell biology in oncology and immunology research. It enables researchers to explore immune checkpoint modulation and therapeutic approaches targeting costimulatory pathways.
There are currently no reviews for this product.